Gain Therapeutics Inc stock is traded at $0.9994, with a volume of 559,109. It is down -4.82% in the last 24 hours and down -16.02% over the past month. Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Previous Close:
$1.05
Open:
$1.02
24h Volume:
559,109
Relative Volume:
0.63
Market Cap:
$44.50M
Revenue:
$55,200
Net Income/Loss:
-$21.24M
P/E Ratio:
-
EPS:
-$0.5885
Net Cash Flow:
-$19.37M
1W Performance:
-3.90%
1M Performance:
-16.02%
6M Performance:
-39.43%
1Y Performance:
-64.93%
1-Day Range:
$0.97$1.10
1-Week Range:
$0.9401$1.30
52-Week Range:
$0.9401$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(301) 500-1556Address
4800 HAMPDEN LANE, BETHESDA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS